Sign in or create an account to add this stock to your watchlist.
About Insulet (NASDAQ:PODD)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of drugs over a specified interval of time, at an administered volume. The company sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:PODD
CUSIP45784P10
Phone978-600-7000
Debt
Debt-to-Equity Ratio3.34
Current Ratio5.48
Quick Ratio5.16
Price-To-Earnings
Trailing P/E Ratio-201.80
Forward P/E Ratio-464.15
P/E GrowthN/A
Sales & Book Value
Annual Sales$463.77 million
Price / Sales11.76
Cash FlowN/A
Price / CashN/A
Book Value$2.90 per share
Price / Book32.01
Profitability
EPS (Most Recent Fiscal Year)($0.46)
Net Income$-26,830,000.00
Net Margins-4.82%
Return on Equity-20.02%
Return on Assets-3.60%
Miscellaneous
Employees857
Outstanding Shares58,740,000
Insulet (NASDAQ:PODD) Frequently Asked Questions
What is Insulet's stock symbol?
Insulet trades on the NASDAQ under the ticker symbol "PODD."
How were Insulet's earnings last quarter?
Insulet Co. (NASDAQ:PODD) announced its quarterly earnings data on Thursday, May, 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, beating the Zacks' consensus estimate of ($0.19) by $0.08. The medical instruments supplier had revenue of $123.60 million for the quarter, compared to analyst estimates of $121.76 million. Insulet had a negative return on equity of 20.02% and a negative net margin of 4.82%. The business's quarterly revenue was up 21.5% compared to the same quarter last year. During the same period last year, the company earned ($0.17) EPS. View Insulet's Earnings History.
When is Insulet's next earnings date?
What price target have analysts set for PODD?
18 brokerages have issued twelve-month price targets for Insulet's shares. Their predictions range from $65.00 to $105.00. On average, they expect Insulet's share price to reach $88.3750 in the next twelve months. View Analyst Ratings for Insulet.
What are Wall Street analysts saying about Insulet stock?
Here are some recent quotes from research analysts about Insulet stock:
- 1. According to Zacks Investment Research, "INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. " (5/9/2018)
- 2. Canaccord Genuity analysts commented, "We maintain our BUY rating on PODD following the announcement that the company has secured two new OUS distributor partnerships with Theras Group (Italy) and Nordic Infucare (Nordic countries) effective July 1, 2018. Both distributors will provide sales, marketing, and customer support in their respective regions. We are encouraged to see PODD not only executing on OUS transition milestones but securing experienced medical device distributors in OUS countries. We believe the market exit by JNJ/Animas has created a unique opportunity for pump players – basically everyone ex Medtronic – to step into existing distribution/service networks who were left looking for new products when JNJ announced it was shuttering Animas. Thus, while not underestimating the resources required to build out an OUS commercial organization, the news of these two partnerships leaves us incrementally confident in Insulet’s ability to facilitate a smooth OUS transition." (5/2/2018)
Who are some of Insulet's key competitors?
Some companies that are related to Insulet include Abiomed (ABMD), ResMed (RMD), Teleflex (TFX), Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Penumbra (PEN), Cantel Medical (CMD), Globus Medical (GMED), Haemonetics (HAE), NovoCure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA), Nevro (NVRO) and iRhythm (IRTC).
Who are Insulet's key executives?
Insulet's management team includes the folowing people:
- Mr. Patrick J. Sullivan, Chairman & CEO (Age 66)
- Ms. Shacey Petrovic, Pres & COO (Age 44)
- Mr. Michael L. Levitz, Sr. VP, CFO & Treasurer (Age 44)
- Mr. Charles Alpuche, Exec. VP & Chief Operations Officer (Age 58)
- Mr. Bradley A. Thomas, Exec. Officer (Age 60)
Has Insulet been receiving favorable news coverage?
Media stories about PODD stock have trended somewhat positive on Sunday, according to Accern. The research group scores the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Insulet earned a news sentiment score of 0.19 on Accern's scale. They also gave media coverage about the medical instruments supplier an impact score of 47.06 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Insulet's major shareholders?
Insulet's stock is owned by many different of retail and institutional investors. Top institutional investors include Frontier Capital Management Co. LLC (3.83%), Lord Abbett & CO. LLC (2.06%), Champlain Investment Partners LLC (1.77%), JPMorgan Chase & Co. (1.32%), Northern Trust Corp (1.29%) and OppenheimerFunds Inc. (1.06%). Company insiders that own Insulet stock include Bradley A Thomas, Charles Alpuche, David A Lemoine, James C Mullen, Jessica Hopfield, John A Fallon, Joseph S Zakrzewski, Michael P Spears, Patrick J Sullivan, Regina O Sommer and Shacey Petrovic. View Institutional Ownership Trends for Insulet.
Which institutional investors are selling Insulet stock?
PODD stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Loomis Sayles & Co. L P, Point72 Asset Management L.P., Champlain Investment Partners LLC, Segall Bryant & Hamill LLC, A.R.T. Advisors LLC, JPMorgan Chase & Co. and Shaker Investments LLC OH. Company insiders that have sold Insulet company stock in the last year include Bradley A Thomas, Charles Alpuche, David A Lemoine, John A Fallon, Michael P Spears and Shacey Petrovic. View Insider Buying and Selling for Insulet.
Which institutional investors are buying Insulet stock?
PODD stock was purchased by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Rockefeller Capital Management L.P., Wasatch Advisors Inc., Carillon Tower Advisers Inc., OppenheimerFunds Inc., KAMES CAPITAL plc, Victory Capital Management Inc. and Frontier Capital Management Co. LLC. Company insiders that have bought Insulet stock in the last two years include Bradley A Thomas, Charles Alpuche, James C Mullen, Jessica Hopfield, Michael P Spears and Patrick J Sullivan. View Insider Buying and Selling for Insulet.
How do I buy shares of Insulet?
Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Insulet's stock price today?
One share of PODD stock can currently be purchased for approximately $92.83.
How big of a company is Insulet?
Insulet has a market capitalization of $5.45 billion and generates $463.77 million in revenue each year. The medical instruments supplier earns $-26,830,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. Insulet employs 857 workers across the globe.
How can I contact Insulet?
Insulet's mailing address is 600 TECHNOLOGY PARK SUITE 200, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]
MarketBeat Community Rating for Insulet (PODD)
MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe PODD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Insulet (NASDAQ:PODD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
18 Wall Street analysts have issued ratings and price targets for Insulet in the last 12 months. Their average twelve-month price target is $88.3750, suggesting that the stock has a possible downside of 4.80%. The high price target for PODD is $105.00 and the low price target for PODD is $65.00. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.78 | 2.70 | 2.61 | 2.67 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $88.3750 | $76.7778 | $72.4667 | $60.5385 |
| Price Target Upside: | 4.80% downside | 13.20% downside | 4.08% downside | 14.30% downside |
Insulet (NASDAQ:PODD) Consensus Price Target History
Insulet (NASDAQ:PODD) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
Insulet (NASDAQ:PODD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Insulet (NASDAQ PODD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.60%
Insulet (NASDAQ PODD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/18/2018 | Michael P. Spears | SVP | Sell | 7,774 | $87.77 | $682,323.98 | |  |
| 5/15/2018 | Michael P. Spears | SVP | Sell | 8,114 | $86.64 | $702,996.96 | | |
| 5/1/2018 | David A. Lemoine | Director | Sell | 1,084 | $84.93 | $92,064.12 | | |
| 3/16/2018 | Bradley A. Thomas | EVP | Sell | 3,500 | $85.00 | $297,500.00 | | |
| 3/15/2018 | Charles Alpuche | COO | Sell | 7,090 | $84.65 | $600,168.50 | | |
| 3/14/2018 | Bradley A. Thomas | EVP | Sell | 7,250 | $83.81 | $607,622.50 | | |
| 3/14/2018 | John A. Fallon | Director | Sell | 9,000 | $84.10 | $756,900.00 | | |
| 3/6/2018 | David A. Lemoine | Director | Sell | 641 | $76.81 | $49,235.21 | | |
| 3/6/2018 | Shacey Petrovic | COO | Sell | 1,319 | $76.81 | $101,312.39 | | |
| 11/13/2017 | James C. Mullen | Director | Buy | 2,500 | $67.45 | $168,625.00 | | |
| 9/6/2017 | Charles Alpuche | EVP | Buy | 2,500 | $58.08 | $145,200.00 | | |
| 5/16/2017 | Michael P. Spears | SVP | Buy | 2,500 | $40.59 | $101,475.00 | | |
| 5/11/2017 | Bradley A. Thomas | EVP | Buy | 3,000 | $38.69 | $116,070.00 | | |
| 5/11/2017 | Jessica Hopfield | Director | Buy | 2,580 | $38.68 | $99,794.40 | | |
| 5/1/2017 | David A. Lemoine | Director | Sell | 1,524 | $43.40 | $66,141.60 | | |
| 3/13/2017 | Regina O. Sommer | Director | Sell | 40,000 | $45.00 | $1,800,000.00 | | |
| 3/6/2017 | David A. Lemoine | Director | Sell | 1,282 | $45.15 | $57,882.30 | | |
| 3/2/2017 | Joseph S. Zakrzewski | Director | Sell | 40,000 | $46.86 | $1,874,400.00 | | |
| 12/9/2016 | Charles Alpuche | SVP | Buy | 6,600 | $37.70 | $248,820.00 | | |
| 12/2/2016 | Patrick J. Sullivan | CEO | Buy | 40,000 | $33.89 | $1,355,600.00 | | |
| 12/1/2016 | Bradley A. Thomas | EVP | Buy | 3,100 | $32.45 | $100,595.00 | | |
| 5/25/2016 | Regina O Sommer | Director | Sell | 8,019 | $30.42 | $243,937.98 | 20,330 | |
| 5/18/2016 | Patrick J Sullivan | CEO | Buy | 45,000 | $27.00 | $1,215,000.00 | 202,795 | |
| 5/13/2016 | Bradley A Thomas | EVP | Buy | 2,975 | $26.63 | $79,224.25 | 51,315 | |
| 5/5/2016 | Bradley A Thomas | EVP | Buy | 1,656 | $30.13 | $49,895.28 | 48,340 | |
| 3/10/2016 | Daniel J Levangie | Insider | Sell | 12,299 | $30.89 | $379,916.11 | 25,358 | |
| 3/7/2016 | Daniel J Levangie | Insider | Sell | 7,663 | $31.15 | $238,702.45 | 9,813 | |
| 3/2/2016 | Jessica Hopfield | Director | Buy | 3,230 | $30.91 | $99,839.30 | 8,838 | |
| 6/5/2015 | Patrick J Sullivan | CEO | Buy | 10,000 | $29.39 | $293,900.00 | | |
| 5/28/2015 | Patrick J Sullivan | CEO | Buy | 20,000 | $27.91 | $558,200.00 | | |
| 5/15/2015 | Timothy J Scannell | Director | Buy | 3,500 | $27.05 | $94,675.00 | | |
| 5/5/2015 | Bradley A Thomas | EVP | Buy | 1,000 | $27.26 | $27,260.00 | | |
| 5/5/2015 | Patrick Ryan | COO | Buy | 3,669 | $26.99 | $99,026.31 | | |
| 4/2/2015 | R Anthony Diehl | General Counsel | Sell | 3,372 | $30.96 | $104,397.12 | | |
| 3/9/2015 | Patrick J Sullivan | CEO | Buy | 10,000 | $31.93 | $319,300.00 | | |
| 3/2/2015 | Charles T Liamos | Director | Sell | 4,000 | $32.00 | $128,000.00 | | |
| 2/12/2015 | Charles T Liamos | Director | Sell | 4,000 | $32.00 | $128,000.00 | | |
| 1/2/2015 | Charles T Liamos | Director | Sell | 4,000 | $46.08 | $184,320.00 | | |
| 11/3/2014 | Charles T Liamos | Director | Sell | 4,000 | $42.95 | $171,800.00 | | |
| 10/1/2014 | Charles T Liamos | Director | Sell | 4,000 | $36.58 | $146,320.00 | | |
| 10/1/2014 | R Anthony Diehl | General Counsel | Sell | 1,250 | $36.59 | $45,737.50 | | |
| 9/10/2014 | Charles T Liamos | Director | Sell | 4,000 | $35.17 | $140,680.00 | | |
| 9/2/2014 | Duane Desisto | CEO | Sell | 20,000 | $36.30 | $726,000.00 | | |
| 8/1/2014 | Duane Desisto | CEO | Sell | 20,000 | $34.23 | $684,600.00 | | |
| 7/1/2014 | Duane Desisto | CEO | Sell | 20,000 | $40.52 | $810,400.00 | | |
| 7/1/2014 | R Anthony Diehl | General Counsel | Sell | 1,250 | $39.65 | $49,562.50 | | |
| 6/11/2014 | R Anthony Diehl | General Counsel | Sell | 17,871 | $37.09 | $662,835.39 | | |
| 6/9/2014 | Peter Devlin | Insider | Sell | 12,314 | $37.10 | $456,849.40 | | |
| 4/8/2014 | Peter Devlin | Insider | Sell | 30,000 | $41.25 | $1,237,500.00 | 79,668 | |
| 4/3/2014 | R Anthony Diehl | General Counsel | Sell | 4,617 | $48.67 | $224,709.39 | 53,246 | |
| 3/6/2014 | R Anthony Diehl | General Counsel | Sell | 12,458 | $49.28 | $613,930.24 | 58,246 | |
| 3/6/2014 | Tracey Haas Wielinski | VP | Sell | 8,275 | $49.21 | $407,212.75 | 24,000 | |
| 2/3/2014 | Charles Liamos | Director | Sell | 11,037 | $42.93 | $473,818.41 | 77,316 | |
| 2/3/2014 | Duane Desisto | CEO | Sell | 20,000 | $42.95 | $859,000.00 | 184,293 | |
| 2/3/2014 | Peter Devlin | Insider | Sell | 30,000 | $42.82 | $1,284,600.00 | 63,081 | |
| 1/3/2014 | Charles Liamos | COO | Sell | 86,000 | $36.02 | $3,097,720.00 | 77,316 | |
| 1/2/2014 | Duane Desisto | CEO | Sell | 20,000 | $36.07 | $721,400.00 | 184,293 | |
| 12/3/2013 | Charles Liamos | COO | Sell | 63,808 | $36.26 | $2,313,678.08 | 118,194 | |
| 11/18/2013 | Charles Liamos | COO | Sell | 80,000 | $35.60 | $2,848,000.00 | 118,194 | |
| 9/3/2013 | Duane Desisto | CEO | Sell | 20,000 | $33.38 | $667,600.00 | 182,433 | |
| 8/29/2013 | Sally Crawford | Director | Sell | 9,000 | $33.42 | $300,780.00 | 7,000 | |
| 8/15/2013 | Regina Sommer | Director | Sell | 5,000 | $33.32 | $166,600.00 | 16,500 | |
| 8/1/2013 | Duane Desisto | CEO | Sell | 20,000 | $31.85 | $637,000.00 | | |
| 7/1/2013 | Duane Desisto | CEO | Sell | 20,000 | $31.51 | $630,200.00 | | |
| 7/1/2013 | Peter Devlin | Insider | Sell | 30,000 | $31.48 | $944,400.00 | | |
| 6/14/2013 | Sally Crawford | Director | Sell | 31,000 | $30.47 | $944,570.00 | | |
| 6/10/2013 | R Anthony Diehl | General Counsel | Sell | 38,455 | $30.50 | $1,172,877.50 | | |
| 6/3/2013 | Duane Desisto | CEO | Sell | 20,000 | $29.76 | $595,200.00 | | |
| 12/3/2012 | Brian K Roberts | CFO | Sell | 10,000 | $21.92 | $219,200.00 | | |
| 11/1/2012 | Brian K Roberts | CFO | Sell | 10,000 | $21.49 | $214,900.00 | | |
| 9/4/2012 | Brian K Roberts | CFO | Sell | 10,000 | $20.78 | $207,800.00 | | |
| 9/4/2012 | Duane Desisto | CEO | Sell | 20,000 | $20.97 | $419,400.00 | | |
| 9/4/2012 | Ruthann Depietro | VP | Sell | 1,000 | $20.90 | $20,900.00 | | |
(Data available from 1/1/2013 forward)
Insulet (NASDAQ PODD) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Insulet Co. (PODD) Expected to Announce Quarterly Sales of $132.89 Million
www.americanbankingnews.com - May 27 at 3:06 AM |
 | Five Top MedTech Stocks in Diabetes
finance.yahoo.com - May 25 at 4:59 PM |
| Brokerages Expect Insulet Co. (PODD) Will Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - May 25 at 11:19 AM |
| Insulet Co. (PODD) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 24 at 9:42 PM |
| Canaccord Genuity Raises Insulet (PODD) Price Target to $100.00
www.americanbankingnews.com - May 23 at 11:55 AM |
| Reviewing Insulet (PODD) and Its Rivals
www.americanbankingnews.com - May 23 at 5:35 AM |
| Insider Selling: Insulet Co. (PODD) SVP Sells 7,774 Shares of Stock
www.americanbankingnews.com - May 22 at 7:28 PM |
 | Global Artificial Pancreas Device Systems Market Growth Opportunities: Medtronic, Insulet Corporation
www.marketwatch.com - May 22 at 8:57 AM |
| Insulet (PODD) & The Competition Critical Review
www.americanbankingnews.com - May 17 at 11:14 PM |
| Insulet (PODD) versus Its Peers Head to Head Comparison
www.americanbankingnews.com - May 17 at 5:10 PM |
| Insider Selling: Insulet Co. (PODD) SVP Sells 8,114 Shares of Stock
www.americanbankingnews.com - May 16 at 7:32 PM |
| Head-To-Head Review: Insulet (PODD) and Its Competitors
www.americanbankingnews.com - May 15 at 5:19 AM |
| Insulet Co. (PODD) Forecasted to Post Q2 2018 Earnings of ($0.14) Per Share
www.americanbankingnews.com - May 11 at 8:35 AM |
| Comparing Insulet (PODD) and The Competition
www.americanbankingnews.com - May 11 at 5:24 AM |
| Endologix (ELGX) vs. Insulet (PODD) Head-To-Head Comparison
www.americanbankingnews.com - May 10 at 5:14 AM |
| Insulet Co. (PODD) Expected to Announce Quarterly Sales of $132.79 Million
www.americanbankingnews.com - May 10 at 4:50 AM |
| Insulet (PODD) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 9 at 3:12 PM |
 | Commit To Purchase Insulet Corp At $65, Earn 5.6% Annualized Using Options
www.nasdaq.com - May 8 at 4:48 PM |
| Insulet (PODD) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 8 at 3:33 PM |
| Analysts Anticipate Insulet Co. (PODD) Will Announce Earnings of -$0.16 Per Share
www.americanbankingnews.com - May 8 at 5:18 AM |
| FY2019 EPS Estimates for Insulet Co. Increased by Piper Jaffray (PODD)
www.americanbankingnews.com - May 7 at 5:01 AM |
| Q2 2019 Earnings Forecast for Insulet Co. (PODD) Issued By William Blair
www.americanbankingnews.com - May 7 at 4:38 AM |
| Insulet Co. (PODD) Forecasted to Post Q1 2019 Earnings of $0.10 Per Share
www.americanbankingnews.com - May 7 at 4:26 AM |
| Insulet Co. Forecasted to Earn Q4 2018 Earnings of $0.01 Per Share (PODD)
www.americanbankingnews.com - May 7 at 4:18 AM |
| Insulet (PODD) Stock Rating Reaffirmed by Northland Securities
www.americanbankingnews.com - May 5 at 12:55 AM |
| Insulet (PODD) PT Set at $90.00 by Oppenheimer
www.americanbankingnews.com - May 4 at 10:31 PM |
| Insulet (PODD) Announces Quarterly Earnings Results, Beats Estimates By $0.08 EPS
www.americanbankingnews.com - May 4 at 5:58 PM |
| Insulet Delivers 21% Revenue Growth and Achieves Operating Profitability Breakeven
finance.yahoo.com - May 4 at 4:44 PM |
| Insulet (PODD) Price Target Increased to $100.00 by Analysts at BMO Capital Markets
www.americanbankingnews.com - May 4 at 3:51 PM |
 | Insulet (PODD) Tops Q1 EPS by 8c
www.streetinsider.com - May 4 at 9:01 AM |
 | Insulet (PODD) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 9:01 AM |
| Edited Transcript of PODD earnings conference call or presentation 3-May-18 8:30pm GMT
finance.yahoo.com - May 4 at 9:01 AM |
| Critical Comparison: Insulet (PODD) & Its Competitors
www.americanbankingnews.com - May 4 at 1:20 AM |
| Insulet (PODD) Price Target Raised to $90.00 at Piper Jaffray
www.americanbankingnews.com - May 3 at 10:04 PM |
| Insulet beats by $0.08, beats on revenue
seekingalpha.com - May 3 at 4:43 PM |
| Insulet Reports First Quarter 2018 Revenue of $123.6 Million, Up 21% Year-Over-Year, and Gross Margin of 61.4%, Up 300 Basis Points, Exceeding Expectations
finance.yahoo.com - May 3 at 4:43 PM |
| Insulet: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 4:43 PM |
| Insulet (PODD) Rating Increased to Strong-Buy at ValuEngine
www.americanbankingnews.com - May 2 at 10:54 PM |
| Insider Selling: Insulet Co. (PODD) Director Sells 1,084 Shares of Stock
www.americanbankingnews.com - May 2 at 7:58 PM |
| Insulet (PODD) Earns "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - May 2 at 1:04 PM |
 | BRIEF-Insulet Establishes Two Significant Commercial Partnerships To Support Its European Expansion
www.reuters.com - May 2 at 9:03 AM |
| Insulet Establishes Two Significant Commercial Partnerships to Support its European Expansion
finance.yahoo.com - May 1 at 4:40 PM |
| Analyzing Insulet (PODD) and Its Competitors
www.americanbankingnews.com - April 30 at 5:21 AM |
| Insulet Co. (PODD) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 29 at 9:30 PM |
| Insulet (PODD) Rating Lowered to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - April 26 at 7:48 AM |
| Insulet (PODD) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - April 26 at 1:56 AM |
| Global Insulin delivery system Market Competitive landscape: Insulet Corporation, Animas Corporation
www.marketwatch.com - April 24 at 9:03 AM |
| Brokerages Anticipate Insulet Co. (PODD) Will Announce Quarterly Sales of $121.60 Million
www.americanbankingnews.com - April 23 at 5:32 AM |
| Zacks: Analysts Expect Insulet Co. (PODD) Will Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - April 21 at 1:20 AM |
| Insulet (PODD) Earns Buy Rating from Analysts at Berenberg Bank
www.americanbankingnews.com - April 20 at 9:22 AM |
Insulet (NASDAQ:PODD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Insulet (NASDAQ:PODD) Income Statement, Balance Sheet and Cash Flow Statement
Insulet (NASDAQ PODD) Stock Chart for Sunday, May, 27, 2018
Loading chart…
